“Instead of floating freely and risking uneven distribution, the 2-micron plasmid has evolved a clever trick of hitchhiking,” ...
The FDA cleared the investigational new drug application for ALX2004, with phase 1 trials expected to begin in mid-2025 for ...
The double ring, spool-like structure of RAD52 protects replicating DNA in dividing cells. A study led by the University of ...
Scientists at the University of Iowa have made an exciting discovery that could lead to new cancer-fighting drugs. They found ...
A revolution is underway in gene editing -- and at its forefront is David Liu, an American molecular biologist whose ...
New precision genome editing technologies are transforming the therapeutic landscape for patients with certain cancers and ...
GenuinePurity™ Liposomal NMN uses liposomal technology for enhanced absorption and is manufactured with 96% purity by Leading ...
First-in-class approach to targeting mitochondrial DNA polymerase (POLG) with disease modifying potential across mitochondrial DNA depletion syndromes ...
Scientists found that pseudouridine helps small RNAs pass on traits and avoid immune detection, offering clues for future RNA ...
The global DNA sequencing services market is poised for significant expansion, with a projected valuation of USD 945.6 million in 2023, expected to surge to USD 2,080.2 million by 2033, according to ...
Daguet, who built acclaimed ventures in France's IoT Valley before branching into web3 development, brings a decade of ...
A study led by scientists at NYU Langone Health sheds light on how the major cancer gene BRCA2 determines which cancer cells can be killed by a class of precision cancer drugs called PARP inhibitors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback